Sabz Biomedicals
cytokine-induced killer cell(Sabz Biomedicals)은 Solid Tumors 표적 세포·유전자 치료로, Colon Cancer Stage IV 영역에서 개발·상용화 중입니다. 작용기전: target cancerous cells upon antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 60건의 관련 임상이 등록되어 있습니다. 차별점: unique designed nanovesicle harnesses the dual therapeutic characteristics: i) multiple immune activation, including PD-1/PD-L.
Solid Tumors
Colon Cancer Stage IV
Active
bispecific T cell engager (BsTCE) fused to the interleukin-15 receptor
retroviral therapy (ART) in HIV/HBV coinfected individuals, partial immune system reconsti
unique designed nanovesicle harnesses the dual therapeutic characteristics: i) multiple immune activation, including PD-1/PD-L
target cancerous cells upon antigen
T cells compared to B7-H3 BsTCE, we performed cytotoxicity
apoptosis-inducing ligands of FasL/TRAIL
PD-1 expression
escape biomarker (PD-L1) among the groups (all p<0
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Sabz Biomedicals
cytokine-induced killer cell(Sabz Biomedicals)은 Solid Tumors 표적 세포·유전자 치료로, Colon Cancer Stage IV 영역에서 개발·상용화 중입니다. 작용기전: target cancerous cells upon antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 60건의 관련 임상이 등록되어 있습니다. 차별점: unique designed nanovesicle harnesses the dual therapeutic characteristics: i) multiple immune activation, including PD-1/PD-L.
Solid Tumors
Colon Cancer Stage IV
Active
bispecific T cell engager (BsTCE) fused to the interleukin-15 receptor
retroviral therapy (ART) in HIV/HBV coinfected individuals, partial immune system reconsti
unique designed nanovesicle harnesses the dual therapeutic characteristics: i) multiple immune activation, including PD-1/PD-L
target cancerous cells upon antigen
T cells compared to B7-H3 BsTCE, we performed cytotoxicity
apoptosis-inducing ligands of FasL/TRAIL
PD-1 expression
escape biomarker (PD-L1) among the groups (all p<0
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.